149. 片側痙攣・片麻痺・てんかん症候群 Hemiconvulsion hemiplegia epilepsy syndrome Clinical trials / Disease details
臨床試験数 : 25 / 薬物数 : 40 - (DrugBank : 14) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-173615 | 22/8/2017 | 15/06/2017 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | Epilepsy and epilepsy syndrome | Intervention name : ucb 34714 INN of the intervention : Brivaracetam Dosage And administration of the intervention : Oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | NULL | recruiting | 16 | 80 | BOTH | 444 | Phase 3 | Japan, Asia except Japan |